Tag: Patient outcomes
Assessing the Cost-Effectiveness of Alzheimer’s Drug Donanemab in the U.K.
The recent decision by the U.K.'s National Institute for Health and Care Excellence (NICE) regarding the cost-effectiveness of the Alzheimer's drug Donanemab, also known as Kisunla, has raised concerns about its accessibility to patients....
New Hope for Endometrial Cancer Patients with FDA-Approved Immunotherapy
The U.S. Food and Drug Administration (FDA) recently approved a new drug for certain adult patients with endometrial cancer. The drug, called Jemperli (dostarlimab-gxly), is an immunotherapy-based drug made by British pharmaceutical company GSK....